![Michael J. Hogan's research works | The Children's Hospital of Philadelphia, PA (CHOP) and other places Michael J. Hogan's research works | The Children's Hospital of Philadelphia, PA (CHOP) and other places](https://www.researchgate.net/profile/Norbert_Pardi/publication/340313439/figure/fig1/AS:875943132413958@1585852525943/figure-fig1_Q320.jpg)
Michael J. Hogan's research works | The Children's Hospital of Philadelphia, PA (CHOP) and other places
![PDF) Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses PDF) Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses](https://i1.rgstatic.net/publication/316527213_Preclinical_and_Clinical_Demonstration_of_Immunogenicity_by_mRNA_Vaccines_against_H10N8_and_H7N9_Influenza_Viruses/links/59025d0b4585156502a302cd/largepreview.png)
PDF) Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses
![Frontiers | Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections | Immunology Frontiers | Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections | Immunology](https://www.frontiersin.org/files/Articles/520377/fimmu-11-00592-HTML-r1/image_m/fimmu-11-00592-g001.jpg)
Frontiers | Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections | Immunology
![Moderna's coronavirus vaccine trial is fully enrolled, 37 percent of participants are minorities - The Washington Post Moderna's coronavirus vaccine trial is fully enrolled, 37 percent of participants are minorities - The Washington Post](https://arc-anglerfish-washpost-prod-washpost.s3.amazonaws.com/public/722KMCAHLEI6XBYZBXYVTUKHSQ.jpg)
Moderna's coronavirus vaccine trial is fully enrolled, 37 percent of participants are minorities - The Washington Post
![Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses: Molecular Therapy Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses: Molecular Therapy](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/9cf7330b-8ae7-442c-9378-eb618ecbd9a2/gr1.jpg)
Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses: Molecular Therapy
![COVID-19 tracker: Regeneron's antibody cocktail hit by safety concerns; Novo's Rybelsus emerging from pandemic slump | FiercePharma COVID-19 tracker: Regeneron's antibody cocktail hit by safety concerns; Novo's Rybelsus emerging from pandemic slump | FiercePharma](https://qtxasset.com/fiercepharma/1597166780/coronavirus.jpg?BmcQIKzuQ5aqGswWWQ2D4IklxjT_mLZE)